trial

Serotonin 1A Agonists and Cognition in Schizophrenia

NCTId NCT00178971
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Northwestern University
Primary completion 2004-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2003-01
Primary completion
2004-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
adjunctive treatment with buspirone

Sponsors

Northwestern UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Herbert Y Meltzer, M.D.Principal Investigator

Sites

1 total
Nashville, United States

Linked catalysts

1
Serotonin 1A Agonists and Cognition in Schizophrenia — primary completion2004-10

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE3
Primary Completion Date
2004-10
Status
COMPLETED
relationships
The graph out of here
drug
adjunctive treatment with buspirone
drug
lead_sponsor
Northwestern University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Herbert Y Meltzer, M.D.
person